Details of the Drug Combinations

General Information of This Drug (ID: DMWFJTR)

• Drug Name: Linagliptin (DMWFJTR)
• Synonyms: Ondero; BI 1356; BI-1356; Ondero (TN); BI-1356-BS; (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione

Indication

Non-insulin dependent diabetes; ICD 11: 5A11; Status: Approved [1]; Type 2 diabetes; ICD 11: 5A11; Status: Approved [2]; Type-2 diabetes; ICD 11: 5A11; Status: Approved [3]; Coronavirus Disease 2019 (COVID-19); ICD 11: 1D6Y; Status: Phase 3 [4]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

50 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Acamprosate + Linagliptin	DCO5AMJ	Acamprosate	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Aliskiren + Linagliptin	DCWCH9P	Aliskiren	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Aprepitant + Linagliptin	DC2SDHB	Aprepitant	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Bortezomib + Linagliptin	DCZIOAT	Bortezomib	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Brincidofovir + Linagliptin	DC49PBP	Brincidofovir	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Cerivastatin + Linagliptin	DC88J77	Cerivastatin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Clascoterone + Linagliptin	DCU2FLN	Clascoterone	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Cytarabine + Linagliptin	DCUYBEG	Cytarabine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Darunavir + Linagliptin	DCL5GX7	Darunavir	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Diazoxide + Linagliptin	DC85NYT	Diazoxide	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Eflornithine + Linagliptin	DCSTA9G	Eflornithine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Fenoprofen + Linagliptin	DC3MLAK	Fenoprofen	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Levamisole + Linagliptin	DCS6573	Levamisole	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Linagliptin + Mebutamate	DCK276G	Mebutamate	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Linagliptin + Dantrolene	DC15KQX	Dantrolene	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Linagliptin + Kanamycin	DC15VHJ	Kanamycin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Linagliptin + Triamterene	DCO1IIO	Triamterene	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Linagliptin + Epinephrine	DCXN4ZB	Epinephrine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Linagliptin + PMID28460551-Compound-2	DCZ6Y2U	PMID28460551-Compound-2	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Linagliptin + Panobinostat	DCPF0L3	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[5]
Linagliptin + Methotrexate	DCL2DMT	Methotrexate	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Linagliptin + Sivelestat	DCXST1D	Sivelestat	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Linagliptin + Anamorelin	DCD1IXQ	Anamorelin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Linagliptin + Everolimus	DCWI4UI	Everolimus	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Linagliptin + IT-141	DCIDZP9	IT-141	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Linagliptin + Terameprocol	DCYXFD7	Terameprocol	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Linagliptin + Chlorzoxazone	DCLMBH2	Chlorzoxazone	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Linagliptin + Phenprocoumon	DC05LBF	Phenprocoumon	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Linagliptin + Daidzin	DCGBXWH	Daidzin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Linagliptin + Tolvaptan	DCWJRA2	Tolvaptan	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Linagliptin + Arfolitixorin	DCVNESL	Arfolitixorin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Linagliptin + Tiagabine	DCG16CR	Tiagabine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Linagliptin + Idarubicin	DC7NRO6	Idarubicin	Glioblastoma? (Cell Line: T98G)	[5]
Linagliptin + Pramipexole	DCZGNZ3	Pramipexole	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Linagliptin + Trimethobenzamide	DC99JEJ	Trimethobenzamide	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Linagliptin + Maprotiline	DCX058R	Maprotiline	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Linagliptin + Endoxifen	DCV874B	Endoxifen	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Linagliptin + Mycophenolic acid	DCO4KGQ	Mycophenolic acid	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Linagliptin + Mefloquine	DCD0J45	Mefloquine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Linagliptin + Sumatriptan	DCP1IMR	Sumatriptan	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Linagliptin + Auranofin	DCRG845	Auranofin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Linagliptin + Cerivastatin	DC6FKF0	Cerivastatin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Linagliptin + Raltegravir	DCJNOPM	Raltegravir	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Memantine + Linagliptin	DCJU074	Memantine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Methylene blue + Linagliptin	DC1B8ST	Methylene blue	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Niclosamide + Linagliptin	DCTMIN9	Niclosamide	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Pramipexole + Linagliptin	DCNJ129	Pramipexole	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Sitagliptin + Linagliptin	DCEA6RP	Sitagliptin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Trioxsalen + Linagliptin	DCO89I3	Trioxsalen	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]
Vinblastine + Linagliptin	DCHIBNC	Vinblastine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[5]

5 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Linagliptin + Glipizide	DC4AIRB	Glipizide	Chronic Kidney Diseases	[6]
Metformin + Linagliptin	DCHU4XJ	Metformin	Diabetic complication	[7]
Insulin-lispro + Linagliptin	DCD2IBQ	Insulin-lispro	Type 2 Diabetes Mellitus	[8]
Linagliptin + Empagliflozin	DC85EFN	Empagliflozin	Type 2 Diabetes Mellitus	[9]
Linagliptin + Acetaminophen	DCT8O9K	Acetaminophen	Diabetes Mellitus, Type 2	[10]

1 Approved Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Linagliptin + Empagliflozin	DCK3417	Empagliflozin	Type-2 diabetes	[11]

References

• [1] Linagliptin FDA Label
• [2] FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 208026
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6318).
• [4] ClinicalTrials.gov (NCT04371978) Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19. U.S. National Institutes of Health.
• [5] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [6] ClinicalTrials.gov (NCT02608177) Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] ClinicalTrials.gov (NCT03320031) A Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin Therapy
• [9] ClinicalTrials.gov (NCT02401880) Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology
• [10] ClinicalTrials.gov (NCT02180334) The Effect of Combination of Mosapride and DPP-4 Inhibitor on Plasma Concentration of Incretin Hormones
• [11] ClinicalTrials.gov (NCT01734785) Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes. U.S. National Institutes of Health.